Market Research Industry Reports

Generics BRIC (Brazil, Russia, India, China) Industry Guide 2017-2021

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Generics BRIC (Brazil, Russia, India, China) Industry Guide 2017-2021

Summary

The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the BRIC generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights

- Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $81,615.2 million in 2016. Russia was the fastest growing country with a CAGR of 15.1% over the 2012-16 period.
- Within the generics industry, China is the leading country among the BRIC nations with market revenues of $57,010.8 million in 2016. This was followed by India, Russia and Brazil with a value of $12,654.0, $6,617.8, and $5,332.6 million, respectively.
- China is expected to lead the generics industry in the BRIC nations with a value of $87,161.6 million in 2021, followed by India, Russia, Brazil with expected values of $18,196.7, $12,616.9 and $10,359.5 million, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC generics market
- Leading company profiles reveal details of key generics market players BRIC operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the BRIC generics market with five year forecasts by both value and volume
- Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country

Reasons to buy

- What was the size of the BRIC generics market by value in 2016?
- What will be the size of the BRIC generics market in 2021?
- What factors are affecting the strength of competition in the BRIC generics market?
- How has the market performed over the last five years?
- How large is the BRIC generics market in relation to its regional counterparts?

Introduction 11
What is this report about? 11
Who is the target reader? 11
How to use this report 11
Definitions 11
BRIC Generics 12
Industry Outlook 12
Generics in Brazil 15
Market Overview 15
Market Data 16
Market Segmentation 18
Market outlook 19
Five forces analysis 21
Macroeconomic indicators 27
Generics in China 29
Market Overview 29
Market Data 30
Market Segmentation 32
Market outlook 33
Five forces analysis 35
Macroeconomic indicators 41
Generics in India 43
Market Overview 43
Market Data 44
Market Segmentation 46
Market outlook 47
Five forces analysis 49
Macroeconomic indicators 55
Generics in Russia 57
Market Overview 57
Market Data 58
Market Segmentation 60
Market outlook 61
Five forces analysis 63
Macroeconomic indicators 69
Company Profiles 71
Leading Companies 71
Appendix 108
Methodology 108
About MarketLine 109

List Of Tables

List of Tables
Table 1: BRIC generics industry, revenue($m), 2012-21
Table 2: BRIC generics industry, revenue($m), 2012-16
Table 3: BRIC generics industry, revenue($m), 2016-21
Table 4: Brazil generics market value: $ million, 2012-16
Table 5: Brazil generics market volume: % of total pharma volume, 2012-16
Table 6: Brazil generics market geography segmentation: $ million, 2016
Table 7: Brazil generics market value forecast: $ million, 2016-21
Table 8: Brazil generics market volume forecast: % of total pharma volume, 2016-21
Table 49: Brazil size of population (million), 2012-16
Table 50: Brazil gdp (constant 2005 prices, $ billion), 2012-16
Table 51: Brazil gdp (current prices, $ billion), 2012-16
Table 52: Brazil inflation, 2012-16
Table 53: Brazil consumer price index (absolute), 2012-16
Table 54: Brazil exchange rate, 2012-16
Table 9: China generics market value: $ billion, 2012-16
Table 10: China generics market volume: % of total pharma volume, 2012-16
Table 11: China generics market geography segmentation: $ billion, 2016
Table 12: China generics market value forecast: $ billion, 2016-21
Table 13: China generics market volume forecast: % of total pharma volume, 2016-21
Table 14: China size of population (million), 2012-16
Table 15: China gdp (constant 2005 prices, $ billion), 2012-16
Table 16: China gdp (current prices, $ billion), 2012-16
Table 17: China inflation, 2012-16
Table 18: China consumer price index (absolute), 2012-16
Table 19: China exchange rate, 2012-16
Table 20: India generics market value: $ million, 2012-16
Table 21: India generics market volume: % of total pharma volume, 2012-16
Table 22: India generics market geography segmentation: $ million, 2016
Table 23: India generics market value forecast: $ million, 2016-21
Table 24: India generics market volume forecast: % of total pharma volume, 2016-21
Table 25: India size of population (million), 2012-16
Table 26: India gdp (constant 2005 prices, $ billion), 2012-16
Table 27: India gdp (current prices, $ billion), 2012-16
Table 28: India inflation, 2012-16
Table 29: India consumer price index (absolute), 2012-16
Table 30: India exchange rate, 2012-16
Table 31: Russia generics market value: $ million, 2012-16
Table 32: Russia generics market volume: % of total pharma volume, 2012-16
Table 33: Russia generics market geography segmentation: $ million, 2016
Table 34: Russia generics market value forecast: $ million, 2016-21
Table 35: Russia generics market volume forecast: % of total pharma volume, 2016-21
Table 36: Russia size of population (million), 2012-16
Table 37: Russia gdp (constant 2005 prices, $ billion), 2012-16
Table 38: Russia gdp (current prices, $ billion), 2012-16
Table 39: Russia inflation, 2012-16
Table 40: Russia consumer price index (absolute), 2012-16
Table 41: Russia exchange rate, 2012-16
Table 42: Ache Laboratorios Farmaceuticos SA: key facts
Table 43: EMS SA: key facts
Table 44: Sanofi SA: key facts
Table 45: Sanofi SA: key financials ($)
Table 46: Sanofi SA: key financials ()
Table 47: Sanofi SA: key financial ratios
Table 48: Eurofarma Laboratorios SA: key facts
Table 55: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
Table 56: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
Table 57: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
Table 58: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
Table 59: Mylan N.V.: key facts
Table 60: Mylan N.V.: key financials ($)
Table 61: Mylan N.V.: key financial ratios
Table 62: Novartis AG: key facts
Table 63: Novartis AG: key financials ($)
Table 64: Novartis AG: key financial ratios
Table 65: Aurobindo Pharma Limited: key facts
Table 66: Aurobindo Pharma Limited: key financials ($)
Table 67: Aurobindo Pharma Limited: key financials (A$)
Table 68: Aurobindo Pharma Limited: key financial ratios
Table 69: Cipla Limited: key facts
Table 70: Cipla Limited: key financials ($)
Table 71: Cipla Limited: key financials (Rs.)
Table 72: Cipla Limited: key financial ratios
Table 73: Lupin Ltd: key facts
Table 74: Lupin Ltd: key financials ($)
Table 75: Lupin Ltd: key financials (Rs.)
Table 76: Lupin Ltd: key financial ratios
Table 77: Sun Pharmaceutical Industries Ltd: key facts
Table 78: Sun Pharmaceutical Industries Ltd: key financials ($)
Table 79: Sun Pharmaceutical Industries Ltd: key financials (Rs.)
Table 80: Sun Pharmaceutical Industries Ltd: key financial ratios
Table 81: Abbott Laboratories: key facts
Table 82: Abbott Laboratories: key financials ($)
Table 83: Abbott Laboratories: key financial ratios
Table 84: Krka, d. d., Novo mesto: key facts
Table 85: Krka, d. d., Novo mesto: key financials ($)
Table 86: Krka, d. d., Novo mesto: key financials ()
Table 87: Krka, d. d., Novo mesto: key financial ratios
Table 88: Teva Pharmaceutical Industries Limited: key facts
Table 89: Teva Pharmaceutical Industries Limited: key financials ($)
Table 90: Teva Pharmaceutical Industries Limited: key financial ratios

List Of Figures

List of Figures
Figure 1: BRIC generics industry, revenue($m), 2012-21
Figure 2: BRIC generics industry, revenue($m), 2012-16
Figure 3: BRIC generics industry, revenue($m), 2016-21
Figure 4: Brazil generics market value: $ million, 2012-16
Figure 5: Brazil generics market volume: % of total pharma volume, 2012-16
Figure 6: Brazil generics market geography segmentation: % share, by value, 2016
Figure 7: Brazil generics market value forecast: $ million, 2016-21
Figure 8: Brazil generics market volume forecast: % of total pharma volume, 2016-21
Figure 9: Forces driving competition in the generics market in Brazil, 2016
Figure 10: Drivers of buyer power in the generics market in Brazil, 2016
Figure 11: Drivers of supplier power in the generics market in Brazil, 2016
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2016
Figure 13: Factors influencing the threat of substitutes in the generics market in Brazil, 2016
Figure 14: Drivers of degree of rivalry in the generics market in Brazil, 2016
Figure 15: China generics market value: $ billion, 2012-16
Figure 16: China generics market volume: % of total pharma volume, 2012-16
Figure 17: China generics market geography segmentation: % share, by value, 2016
Figure 18: China generics market value forecast: $ billion, 2016-21
Figure 19: China generics market volume forecast: % of total pharma volume, 2016-21
Figure 20: Forces driving competition in the generics market in China, 2016
Figure 21: Drivers of buyer power in the generics market in China, 2016
Figure 22: Drivers of supplier power in the generics market in China, 2016
Figure 23: Factors influencing the likelihood of new entrants in the generics market in China, 2016
Figure 24: Factors influencing the threat of substitutes in the generics market in China, 2016
Figure 25: Drivers of degree of rivalry in the generics market in China, 2016
Figure 26: India generics market value: $ million, 2012-16
Figure 27: India generics market volume: % of total pharma volume, 2012-16
Figure 28: India generics market geography segmentation: % share, by value, 2016
Figure 29: India generics market value forecast: $ million, 2016-21
Figure 30: India generics market volume forecast: % of total pharma volume, 2016-21
Figure 31: Forces driving competition in the generics market in India, 2016
Figure 32: Drivers of buyer power in the generics market in India, 2016
Figure 33: Drivers of supplier power in the generics market in India, 2016
Figure 34: Factors influencing the likelihood of new entrants in the generics market in India, 2016
Figure 35: Factors influencing the threat of substitutes in the generics market in India, 2016
Figure 36: Drivers of degree of rivalry in the generics market in India, 2016
Figure 37: Russia generics market value: $ million, 2012-16
Figure 38: Russia generics market volume: % of total pharma volume, 2012-16
Figure 39: Russia generics market geography segmentation: % share, by value, 2016
Figure 40: Russia generics market value forecast: $ million, 2016-21
Figure 41: Russia generics market volume forecast: % of total pharma volume, 2016-21
Figure 42: Forces driving competition in the generics market in Russia, 2016
Figure 43: Drivers of buyer power in the generics market in Russia, 2016
Figure 44: Drivers of supplier power in the generics market in Russia, 2016
Figure 45: Factors influencing the likelihood of new entrants in the generics market in Russia, 2016
Figure 46: Factors influencing the threat of substitutes in the generics market in Russia, 2016
Figure 47: Drivers of degree of rivalry in the generics market in Russia, 2016
Figure 48: Sanofi SA: revenues & profitability
Figure 49: Sanofi SA: assets & liabilities
Figure 50: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability
Figure 51: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities
Figure 52: Mylan N.V.: revenues & profitability
Figure 53: Mylan N.V.: assets & liabilities
Figure 54: Novartis AG: revenues & profitability
Figure 55: Novartis AG: assets & liabilities
Figure 56: Aurobindo Pharma Limited: revenues & profitability
Figure 57: Aurobindo Pharma Limited: assets & liabilities
Figure 58: Cipla Limited: revenues & profitability
Figure 59: Cipla Limited: assets & liabilities
Figure 60: Lupin Ltd: revenues & profitability
Figure 61: Lupin Ltd: assets & liabilities
Figure 62: Sun Pharmaceutical Industries Ltd: revenues & profitability
Figure 63: Sun Pharmaceutical Industries Ltd: assets & liabilities
Figure 64: Abbott Laboratories: revenues & profitability
Figure 65: Abbott Laboratories: assets & liabilities
Figure 66: Krka, d. d., Novo mesto: revenues & profitability
Figure 67: Krka, d. d., Novo mesto: assets & liabilities
Figure 68: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 69: Teva Pharmaceutical Industries Limited: assets & liabilities

Global Generics Industry Profile & Value Chain Analysis

Global Generics Industry Profile & Value Chain AnalysisGlobal Generics industry profile provides top-line qualitative and quantitative information including: market size (value and volume 2012-16, and forecast to 2021). The

USD 495View Report

Generics Global Industry Guide 2017-2021

Generics Global Industry Guide 2017-2021Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains

USD 1495View Report

Confectionery BRIC (Brazil, Russia, India, China) Industry Guide 2013-2022

Confectionery BRIC (Brazil, Russia, India, China) Industry Guide 2013-2022The BRIC Confectionery industry profile provides top-line qualitative and quantitative information including: market share, market size (value and volume 2013-17, and

USD 995View Report

Breakfast Cereals BRIC (Brazil, Russia, India, China) Industry Guide 2013-2022

Breakfast Cereals BRIC (Brazil, Russia, India, China) Industry Guide 2013-2022The BRIC Breakfast Cereals industry profile provides top-line qualitative and quantitative information including: market share, market size (value and volume

USD 995View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 995
  • Site Licence    USD 1990
  • Enterprise Wide Licence    USD 2985
$ 995

Reports Details

Published Date : Feb 2018
No. of Pages :110
Country :BRIC
Category :Pharmaceuticals and Healthcare
Publisher :MarketLine
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube